Evidence map›Paper›PMID 40353215›Full record

ArticleDEN open2026

Adequacy evaluation of 22-gauge needle endoscopic ultrasound-guided tissue acquisition samples and glass slides preparation for successful comprehensive genomic profiling testing: A single institute experience.

Tami Nagatani, Yoji Wani, Masahiro Takatani, Soichiro Fushimi, Hirofumi Inoue, Shinichiro Hori, Kyohei Kai, Hideki Yamamoto, Tetsuya Okazaki, Maki Tanioka and 2 more

Abstract read
In one paragraph

Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tami NagataniDepartment of Pathology Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.ORCID https://orcid.org/0009-0004-9651-1784
Yoji WaniDepartment of Pathology Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Masahiro TakataniDepartment of Internal Medicine Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Soichiro FushimiDepartment of Pathology Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Hirofumi InoueDivision of Medical Support Dentistry and Pharmaceutical Science Okayama University Graduate School of Medicine Okayama Japan.
Shinichiro HoriDepartment of Internal Medicine Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Kyohei KaiDepartment of Genetic Medicine Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Hideki YamamotoDepartment of Genetic Medicine Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Tetsuya OkazakiDepartment of Genetic Medicine Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Maki TaniokaClinical Genomic Medicine Dentistry and Pharmaceutical Science Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan.
Hiroyuki OkadaDepartment of Internal Medicine Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.
Akira HirasawaDepartment of Genetic Medicine Japanese Red Cross Society Himeji Red Cross Hospital Hyogo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22-gauge needle (22G) through endoscopic ultrasound-guided fine needle acquisition (EUS-TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical practice. Methods: Between June 2019 and April 2024, 119 samples of 22G EUS-TA collected for F1CDx testing at Himeji Red Cross Hospital were retrospectively reviewed. Tissue adequacy was only assessed based on tumor cell percentage (≥20%). The procedure stopped when white tissue fragments reached 20 mm during macroscopic on-site evaluation. The specimens were prepared using both 'tissue preserving sectioning' to retain tissue within formalin-fixed paraffin-embedded blocks and the 'thin sectioning matched needle gauge and tissue length' method with calculation to ensure minimal unstained slides for the 1 mm Results: Of 119 samples, 108 (90.8%) were suitable for F1CDx. Excluding the cases not submitted for testing, in the 45 cases where F1CDx was done using 22G EUS-TA samples, eight (17.8%) had a sum of tissue area tissue of 25 mm Conclusions: The 22G EUS-TA needle is an effective tool for providing the sufficient tissue volume required for F1CDx.

Indexed as

biliary tract cancercomprehensive genomic profilingendoscopic ultrasound‐guided fine needle aspirationendoscopic ultrasound‐guided fine needle biopsypancreatic cancer

Identifiers

PMID40353215
PMCPMC12064553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.